Structure of Abemaciclib
CAS No.: 1231929-97-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Abemaciclib is a selective CDK4/6 inhibitor with IC50 values of 2 nM for CDK4 and 10 nM for CDK6. Abemaciclib has antitumor effects and is used in research on HR+/HER2- breast cancer and other tumors.
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1231929-97-7 |
Formula : | C27H32F2N8 |
M.W : | 506.59 |
SMILES Code : | CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C |
MDL No. : | MFCD22665744 |
InChI Key : | UZWDCWONPYILKI-UHFFFAOYSA-N |
Pubchem ID : | 46220502 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302 |
Precautionary Statements: | P280-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
MCF7 | 500 nM | 7 days | To study the effect of Abemaciclib on chromatin accessibility in MCF7 cells, results showed that Abemaciclib induced widespread chromatin remodeling. | PMC8115221 |
MDA-MB-453 | 500 nM | 7 days | To study the effect of Abemaciclib on chromatin accessibility in MDA-MB-453 cells, results showed that Abemaciclib induced widespread chromatin remodeling. | PMC8115221 |
Human primary fibroblasts (BJ) | 1 µM | 8 days | Abemaciclib induced cell cycle arrest, characterized by reduced RB phosphorylation, downregulation of E2F2, and increased p16 expression. Proliferation was not restored after drug withdrawal. | PMC8922251 |
Human primary fibroblasts (WI38) | 1 µM | 8 days | Abemaciclib induced cell cycle arrest, characterized by reduced proliferation, and proliferation was not restored after drug withdrawal. | PMC8922251 |
A549 cells | 10 µM | 24 h | To evaluate the inhibitory effect of Abemaciclib and P2shortA on the proliferation of A549 cells. Results showed that P2shortA significantly inhibited A549 cell proliferation at 5-10 µM, and exhibited a synergistic effect when combined with Abemaciclib. | PMC7019173 |
H358 cells | 10 µM | 24 h | To evaluate the inhibitory effect of Abemaciclib and P2shortA on the proliferation of H358 cells. Results showed that P2shortA significantly inhibited H358 cell proliferation at 5-10 µM, and exhibited a synergistic effect when combined with Abemaciclib. | PMC7019173 |
PC9 cells | 10 µM | 24 h | To evaluate the inhibitory effect of Abemaciclib and P2shortA on the proliferation of PC9 cells. Results showed that P2shortA significantly inhibited PC9 cell proliferation at 5-10 µM, and exhibited a synergistic effect when combined with Abemaciclib. | PMC7019173 |
MCF7 | 0.1 μM to 20 μM | 6 months | To construct MCF7 cells resistant to Abemaciclib and observe the expression changes of PARP1 and p-YB-1. The results showed that with the increase of Abemaciclib concentration, the expression of PARP1 and p-YB-1 was significantly upregulated. | PMC10687910 |
MCF7AR | 50 μM | To evaluate the resistance of MCF7AR cells to Abemaciclib and verify the expression levels of PARP1 and p-YB-1. The results showed that the IC50 of MCF7AR cells to Abemaciclib was significantly higher than that of MCF7 cells, and the expression of PARP1 and p-YB-1 was upregulated. | PMC10687910 | |
MCF7 cells | 100 nM | 24 h | Abemaciclib significantly inhibited the kinase activity of CDK4 but had a weaker effect on CDK6. | PMC8831444 |
MCF7 FAT1-loss cells | 100 nM | 24 h | Abemaciclib significantly inhibited the kinase activity of CDK4 but had a weaker effect on CDK6. | PMC8831444 |
HCC1428-LTED-AbemaR | 250 nM | 6-12 months | To evaluate the anti-proliferative effect of Abemaciclib in CDK4/6 inhibitor-resistant cells. Results showed that Abemaciclib inhibited the growth of resistant cells in both short-term and long-term proliferation assays, although the extent of inhibition was reduced compared to sensitive cells. | PMC6921513 |
MCF7-LTED-D538G-AbemaR | 250 nM | 6-10 months | To evaluate the anti-proliferative effect of Abemaciclib in ESR1-mutant CDK4/6 inhibitor-resistant cells. Results showed that Abemaciclib inhibited the growth of resistant cells in both short-term and long-term proliferation assays, although the extent of inhibition was reduced compared to sensitive cells. | PMC6921513 |
HER2+ breast cancer cell lines | 2 µM | 24 hours | Evaluate the effect of Sitravatinib combined with CDK4/6 inhibitors on HER2+ breast cancer cells, showing lower sensitivity compared to TNBC cells. | PMC11202171 |
TNBC cell lines | 2 µM | 24 hours | Evaluate the effect of Sitravatinib combined with CDK4/6 inhibitors on TNBC cells, showing significant suppression of Met, Axl, and MerTK activities. | PMC11202171 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | A375 BRAF-mutated melanoma xenografts | Oral | 45 mg/kg or 90 mg/kg | Once a day for 56 days | To assess the time course of abemaciclib-mediated target engagement and cell cycle arrest in A375 xenograft tumours, the model successfully described the concentration-dependent time course of pRb, TopoIIa, and pHH3. | PMC4800303 |
mice | 786-O cell orthotopic xenografts | oral gavage | 60 mg/kg | twice daily for 25 days | Abemaciclib suppressed the growth of 786-O xenograft tumors. | PMC6913182 |
Mice | PDX 14-07 | Oral | 90 mg/kg | Once daily for 21 to 28 days | To study the effect of Abemaciclib on the PDX 14-07 tumor model, results showed that Abemaciclib induced marked gains in H3K27ac. | PMC8115221 |
Mice | p16-3MR mice | Intraperitoneal injection | 50 mg/kg | Once daily for 7 days | Abemaciclib induced p16 expression and SA-β-gal activity in the kidneys of mice, indicating the induction of cellular senescence, but did not cause significant physical performance decline or changes in blood counts. | PMC8922251 |
Mice | H358 orthotopic lung cancer model | Oral | 10 mg/kg | Once daily for three weeks | To evaluate the inhibitory effect of Abemaciclib on the growth of H358 orthotopic lung tumors. Results showed that Abemaciclib alone slightly inhibited tumor growth, while the combination with P2shortA completely inhibited tumor growth. | PMC7019173 |
Nude mice | MDA-MB-231 and MCF7AR xenograft models | Oral and intraperitoneal injection | 100 mg/kg | Three times a week | To evaluate the inhibitory effect of combined treatment with Abemaciclib and Olaparib or LJI308 on tumor growth. The results showed that the combined treatment significantly inhibited tumor growth and induced apoptosis of tumor cells. | PMC10687910 |
Mice | MCF7 FAT1-loss xenograft model | Intraperitoneal injection | 25 mg/kg | 3 consecutive days | BSJ-05-017 significantly inhibited the activity of CDK4 and CDK6 and reduced the phosphorylation level of RB1. | PMC8831444 |
Nude mice | ST941-HI PDX model | Oral | 10 mg/kg | Daily for 150 days | To evaluate the anti-tumor activity of Abemaciclib in CDK4/6 inhibitor-resistant PDX models. Results showed that Abemaciclib caused significant tumor growth inhibition in models continuously exposed to Fulvestrant and Palbociclib, indicating that these tumors retain ER-dependent tumor growth despite prior CDK4/6 inhibitor treatment. | PMC6921513 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT04750928 | Neurofibromatosis 1 | PHASE1|PHASE2 | RECRUITING | 2029-12-31 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less << |
NCT02387814 | Hepatic Insufficiency | PHASE1 | COMPLETED | 2025-08-15 | DaVita Clinical Research, Lake... More >>wood, Colorado, 80228, United States|Clinical Pharmacology of Miami (CPMI), Miami, Florida, 33014, United States|Orlando Clinical Research Center (OCRC), Orlando, Florida, 32809, United States|Indiana University - Digestive and Liver Diseases, Indianapolis, Indiana, 46202, United States|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States Less << |
NCT03310879 | Cancer | PHASE2 | RECRUITING | 2026-04-30 | Dana Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States Less << |
NCT03130439 | Breast Cancer | PHASE2 | TERMINATED | 2022-01-30 | Dana-Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States Less << |
NCT02102490 | Metastatic Breast Cancer | PHASE2 | COMPLETED | 2018-10-22 | Northern Arizona Hematology & ... More >>Oncology Associates, Sedona, Arizona, 86336, United States|HOPE Hematology Oncology Physicians and Extenders, Tucson, Arizona, 85704, United States|Arizona Clinical Research Center, Tucson, Arizona, 85715, United States|Univ of California San Francisco, San Francisco, California, 94115, United States|Sansum Medical Research Foundation, Santa Barbara, California, 93105, United States|Rocky Mountain Cancer Center, Denver, Colorado, 80220, United States|Washington Hospital Center, Washington, District of Columbia, 20010, United States|Florida Cancer Specialists, Fort Myers, Florida, 33916, United States|Advanced Medical Specialties, Miami, Florida, 33176, United States|Florida Cancer Specialists, Saint Petersburg, Florida, 33705, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, 21044, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Minnesota Oncology/Hematology PA, Minneapolis, Minnesota, 55404, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, 45242, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, 37203, United States|Texas Oncology Cancer Center, Austin, Texas, 78731, United States|Texas Oncology - Bedford, Bedford, Texas, 76022, United States|Presbyterian Hospital Dallas, Dallas, Texas, 75231, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104, United States|Texas Oncology-Memorial City, Houston, Texas, 77024, United States|Texas Oncology-Plano West, Plano, Texas, 75093, United States|Texas Oncology-Sherman, Sherman, Texas, 75090-0504, United States|US Oncology, The Woodlands, Texas, 77380, United States|Tyler Cancer Center, Tyler, Texas, 75702, United States|Northwest Cancer Specialists PC, Vancouver, Washington, 98684, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussel, 1000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, 6000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, 3000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, 4000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, 21034, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, 75248, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, 08035, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, 28007, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, 46015, Spain Less << |
NCT03703466 | Metastatic Breast Cancer | PHASE2 | COMPLETED | 2023-03-09 | Mater Private Hospital, North ... More >>Sydney, New South Wales, 2291, Australia|St Vincent's Hospital, Sydney, New South Wales, 2010, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, 5037, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, 3000, Belgium|Russian Oncological Research Center, Moscow, 115478, Russian Federation|Volgograd regional clinical oncology dispensary, Volgograd, 400138, Russian Federation|Hospital Quirón Salud Barcelona-Instituto Oncológico Baselga, Barcelona, 08023, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Ruber Internacional, Madrid, 28034, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Akdeniz University Medical Faculty, Antalya, 07058, Turkey|Trakya University Faculty of Medicine, Edirne, 22030, Turkey|Medical Park Izmir Hospital, Izmir, 35575, Turkey|Inonu University Medical Faculty, Malatya, 44280, Turkey Less << |
NCT03837821 | Bladder Cancer | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | 2025-12-25 | Moffitt Cancer Center, Tampa, ... More >>Florida, 33612, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, 11217, United States|Weill Cornell Medicine, New York, New York, 10065, United States|UT Southwestern Medical Center - Simmons Comprehensive Cancer Center, Dallas, Texas, 75390, United States Less << |
NCT02482935 | Healthy | PHASE1 | COMPLETED | 2025-09-15 | Covance Clinical Research Unit... More >>, Daytona Beach, Florida, 32117, United States|Covance Clinical Research Unit, Dallas, Texas, 75247, United States Less << |
NCT01739309 | Mantle Cell Lymphoma | PHASE2 | COMPLETED | 2022-09-05 | For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, 59037, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pessac, 33604, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Homburg, 66421, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kassel, 34125, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, 55131, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nürnberg, 90419, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, 89081, Germany Less << |
NCT03763604 | Metastatic Breast Cancer | APPROVED_FOR_MARKETING | - | Liverpool Hospital, Liverpool,... More >> New South Wales, 2170, Australia|North West Cancer Centre, North Tamworth, New South Wales, 2340, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, 2010, Australia|Mater Hospital Sydney, Sydney, New South Wales, 2060, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Wollongong Hospital, Wollongong, New South Wales, 2500, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Adelaide Oncology and Haematology, Calvary Central Districts Hospital, Elizabeth Vale, South Australia, 5112, Australia|Icon Cancer Centre - Hobart, Hobart, Tasmania, 7000, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7001, Australia|Box Hill Hospital Outpatients, Box Hill, Victoria, 3128, Australia|Epworth Eastern Hospital, Box Hill, Victoria, 3128, Australia|Melbourne Cancer Care, Brighton, Victoria, 3186, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Dr. Zimet Private Room, Richmond, Victoria, 3121, Australia|Slade Pharmacy Epworth Hospital, Richmond, Victoria, 3121, Australia|Goulburn Valley Health, Shepparton, Victoria, 3630, Australia|Icon Cancer Care - The Wesley Medical Centre, Auchenflower, 4066, Australia|Northern Beaches Hospital, Freches Forest, 2086, Australia|South Coast District Hospital, Victor Harbor, 5211, Australia|Tom Baker Cancer Center, Calgary, Alberta, T2N4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer Vancouver, Vancouver, British Columbia, V5Z 4E6, Canada|British Columbia Cancer Agency - Vancouver Island, Victoria, British Columbia, V8R 6V5, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, N2G 1G3, Canada|The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|Algoma District Cancer Program, Sault Ste. Marie, Ontario, P6B 0A8, Canada|Unity Health Toronto, St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada|CHUL du CHU de Québec, Québec City, Quebec, G1V 4G2, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, S7N 4H4, Canada|Cairo Oncology Center (Cairo Cure), Mohandeseen, Cairo, 12655, Egypt|Apollo Cancer Institute, Apollo Speciality Hospital, Teynampet, Chennai, 600018, India|Indraprastha Apollo Hospital, New Delhi, 110076, India|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Torre, Roma, 00133, Italy|Istituto Oncologico Veneto IRCCS, Padova, Veneto, 35128, Italy|Ospedale Di Circolo E Fondazione Macchi, Varese, 21100, Italy|National Cancer Center, Ilsandong-gu, Goyang-si Gyeonggi-do, 10408, Korea, Republic of|National Cancer Center, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|Inha University Hospital, Incheon, Incheon-gwangyeoksi [Incheon], 22332, Korea, Republic of|St. Mary's Hospital, Gyeonggi-do, Korea, 11765, Korea, Republic of|Gachon University Gil Medical Center, Namdong-gu, Incheon, Korea, 21556, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, 06591, Korea, Republic of|National Cancer Center, Goyang-si, Kyǒnggi-do, 10408, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul, Korea, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul], 03722, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 06351, Korea, Republic of|Ewha University Mokdong Hospital, Seoul, Yangcheon-gu, 07985, Korea, Republic of|Chungbuk National University Hospital, Chungcheongbuk-do, 28644, Korea, Republic of|Kyungpook National University Medical Center Chilgok Hospital, Daegu, 41404, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Gangnam Severance Hospital, Seoul, 06273, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Pantai Hospital Sungai Petani, Sungai Petani, Kedah, 08000, Malaysia|Gleneagles Penang, Georgetown, Penang, 10050, Malaysia|Penang Adventist Hospital, Georgetown, Penang, 11350, Malaysia|Mount Miriam Cancer Hospital, Tanjung Bungah, Penang, 11200, Malaysia|Beacon Hospital, Off Jalan Templer, Petaling JAYA, 46050, Malaysia|Pantai Hospital Penang, Bayan BARU, Pulau Pinang, 11900, Malaysia|Loh Guan Lye Specialists' Centre, Georgetown, Pulau Pinang, 10400, Malaysia|Hospital Umum Sarawak, Kuching, Sarawak, 93586, Malaysia|Subang Jaya Medical Centre, Petaling Jaya, Selangor, 47500, Malaysia|Pantai Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekutuan, 59100, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, 50586, Malaysia|Universiti Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia|University Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia|Institut Kanser Negara, Putrajaya, 62250, Malaysia|Elizabeth Au Oncology, Singapore, 228510, Singapore|Vincent Pallotti Hospital, Pinelands, Cape Town, 7405, South Africa|Flora Clinic, Floracliff, Gauteng, 1715, South Africa|Olivedale Clinic, Johannesburg, Gauteng, 2158, South Africa|Netcare Linksfield Hospital, Johannesburg, Gauteng, 2192, South Africa|Donald Gordon Medical Center, Johannesburg, Gauteng, 2193, South Africa|Wits Donald Gordon Clinical Trial Center, Johannesburg, Gauteng, 2193, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, 2196, South Africa|Sandton Oncology, Morningside, Gauteng, 2196, South Africa|DGMC Oncology, Parktown, Gauteng, 2193, South Africa|Amanzimtoti Oncology Centre, Durban, KwaZulu-Natal, 4126, South Africa|Hopelands Cancer Centre Hilton, Hilton, KZN, 3245, South Africa|Abraham Oncology, Richards Bay, KZN, 3900, South Africa|Cancercare, George, Western Cape, 7764, South Africa|Dr Pirjol and Szpak Inc. Oncology Pratice, Amanzimtoti, 4126, South Africa|Cancercare Rondebosch Oncology, Cape Town, 7700, South Africa|Hospital Virgen de los Lirios, Alcoy, Alicante, 03800, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Andalucía, 29010, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], 8035, Spain|Hospital Universitari General de Catalunya, Sant Cugat del Vallès, Barcelona [Barcelona], 08915, Spain|Hospital Universitari de Girona Dr. Josep Trueta, Girona, Barcelona, 17007, Spain|Hospital Duran I Reynals, Hospitalet De Llobregat, Barcelona, 08908, Spain|Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Barcelona, 08208, Spain|Hospital Germans Trias i Pujol, Badalona, Catalunya [Catalu?a], 08916, Spain|Hospital Universitario de Canarias, Tenerife, La Laguna, 38320, Spain|Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad De, 28034, Spain|Hospital la Zarzuela, Aravaca, Madrid, 28023, Spain|Hospital De Mostoles, Mostoles, Madrid, 28935, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, 30120, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Palma De Mallorca(Baleares), 07120, Spain|H. San Francisco de Borja (H. GANDIA), Gandia, Valencia, 46702, Spain|Hospital Lluis Alcanyis, Xativa, Valencia, 46800, Spain|Hospital De Basurto, Bilbao, Vizcaya, 48013, Spain|Hospital General de Albacete, Albacete, 02006, Spain|Hospital Quironsalud Barcelona- END, Barcelona, 08023, Spain|Hospital Quirón Salud Barcelona-Instituto Oncológico Baselga, Barcelona, 08023, Spain|Hospital Universitari Dexeusa, Barcelona, 08028, Spain|Instituto Oncologico Dr Rosell (IOR), Barcelona, 08028, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Arquitecto Marcide (área Sanitaria de Ferrol), Coru?a, 15405, Spain|Hospital Universitario San Cecilio, Granada, 18016, Spain|Cl. Universitaria Navarra, Madrid, 28022, Spain|Centro Oncológico MD Anderson, Madrid, 28033, Spain|Hospital Ruber Internacional, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Madrid Norte Sanchinarro, Madrid, 28050, Spain|Hospital Infanta Cristina, Madrid, 28981, Spain|Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, 37007, Spain|Fundación Instituto Valenciano de Oncología, Valencia, 46009, Spain|Hospital Clinico Universitario Valencia, Valencia, 46010, Spain|Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain|Hospital Arnau de Vilanova Valencia, Valencia, 46015, Spain|Hospital Doctor Peset, Valencia, 46017, Spain|Hospital de Sagunto, Valencia, 46500, Spain|IDCQ HOSPITALES Y SANIDAD, S.L.U. (Hospital Quirón Zaragoza), Zaragoza, 50006, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Hospital Universitario Zaragoza, Zaragoza, 50009, Spain|Universit?tsspital Basel, Basel, Basel Stadt, 4031, Switzerland|H?pital de la Tour, La Tour H?pital Privé SA, Meyrin, Geneva, 1217, Switzerland|Tumorzentrum ZeTuP Rapperswil-Jona, Rapperswil, Saint Gallen, 8640, Switzerland|Tumor- und Brustzentrum ZeTuP Sankt Gallen, St. Gallen, Saint Gallen, 9000, Switzerland|Cantonal Hospital St.Gallen, st.Gallen, Sankt Gallen, 9007, Switzerland|Oncologia Varini Calderoni Christinat, Lugano, Ticino, 6900, Switzerland|H?pitaux Universitaires de Genève, Geneva, 1205, Switzerland|HUG-H?pitaux Universitaires de Genève, Genève, 1211, Switzerland|Luzerner Kantonsspital, Luzern, 6000, Switzerland|OnkoZentrum Zürich AG, Zürich, 8038, Switzerland|Chiayi Chang Gung Memorial Hospital, Putzu City, Chiayi County, 61363, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Niaosong Dist, Kaohsiung City, 833, Taiwan|Tri-Service General Hospital, Taipei City, Taipei, 114, Taiwan|National Taiwan University Hospital Yunlin Branch, Zhongzheng District, Taipei, 10048, Taiwan|MacKay Memorial Hospital, New Taipei City, Tamsui District, 251, Taiwan|Taichung Tzu Chi Hospital, Taichung, Tanzi District, 427, Taiwan|Saint Paul's Hospital, Taoyuan, Taoyuan District, 330, Taiwan|Kaohsiung Municipal Siaogang Hospital, Kaohsiung City, 812, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|China Medical University Hospital, Taichung, 40447, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|Taipei Veterans General Hospital, Taipei City, 11217, Taiwan|National Taiwan University Hospital, Taipei, 100229, Taiwan|Mackay Memorial Hospital, Taipei, 10449, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Koo Foundation Sun Yan-Sen Cancer Center, Taipei, 112, Taiwan|National Taiwan University Hospital Yunlin Branch, Yunlin County, Douliu City, 64041, Taiwan|Maharaj Nakorn Chiang Mai Hospital, Muang Chiangmai, Chiangmai, 50200, Thailand|Rajavithi Hospital, Bangkok, Ratchathewi District, 10400, Thailand|Songklanagarind Hospital, Hat Yai, Songkhla, 90110, Thailand|King Chulalongkorn Memoiral Hospsital, Bangkok, 10330, Thailand|Ramathibodi Hopsital, Bangkok, 10400, Thailand|Addenbrookes Hospital, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|Loom Dene, Radlett, Hertfordshire, WD7 8AA, United Kingdom|Northern Centre for Cancer Treatment, Newcastle Upon Tyne, Tyne And Wear, NE7 7DN, United Kingdom Less << | |
NCT02919696 | Advanced Cancer|Metastatic Can... More >>cer Less << | PHASE1 | COMPLETED | 2019-09-03 | For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changsha, 410013, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, 200030, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China Less << |
NCT04003896 | Biliary Tract Carcinoma | PHASE2 | TERMINATED | 2023-08-15 | Penn State Cancer Institute, H... More >>ershey, Pennsylvania, 17033-0850, United States Less << |
NCT04408924 | Metastatic Castration-Resistan... More >>t Prostate Cancer Less << | PHASE2 | COMPLETED | 2023-06-02 | University of Utah - Huntsman ... More >>Cancer Institute, Salt Lake City, Utah, 84112, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Centre Leon Berard, Lyon Cedex 08, 69373, France|Institut Paoli-Calmettes, Marseille, 13273, France|Hopital Europeen Georges Pompidou, Paris, 75015, France|Institut Claudius Regaud, Toulouse cedex 9, 31059, France|Gustave Roussy, Villejuif Cedex, 94805, France|Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Barcelona, 08208, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain Less << |
NCT04681768 | Breast Cancer/ Metastatic Brea... More >>st Cancer Less << | RECRUITING | 2025-12-24 | Klinikum rechts der Isar der T... More >>U München, Klinik und Poliklinik für Frauenheilkunde, Munich, 81675, Germany Less << | |
NCT04169074 | HNSCC | PHASE2 | RECRUITING | 2025-06-30 | University of Arizona, Tucson,... More >> Arizona, 85719, United States Less << |
NCT04941274 | Kaposi Sarcoma | PHASE1|PHASE2 | RECRUITING | 2028-06-01 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less << |
NCT02644460 | Diffuse Intrinsic Pontine Glio... More >>ma|Brain Tumor, Recurrent|Solid Tumor, Recurrent|Neuroblastoma, Recurrent, Refractory|Ewing Sarcoma, Recurrent, Refractory|Rhabdomyosarcoma, Recurrent, Refractory|Osteosarcoma, Recurrent, Refractory|Rhabdoid Tumor, Recurrent, Refractory Less << | PHASE1 | COMPLETED | 2023-10-10 | Phoenix Children's Hospital, P... More >>hoenix, Arizona, 85016, United States|Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Children's Healthcare of Atlanta, Egleston, Atlanta, Georgia, 30322, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, 30342, United States Less << |
NCT03356587 | HNSCC|Head and Neck Neoplasms | PHASE2 | UNKNOWN | 2020-12-31 | Seoul National University Hosp... More >>ital, Seoul, 110-744, Korea, Republic of Less << |
NCT04040205 | Chondrosarcoma|Osteosarcoma|So... More >>ft Tissue Sarcoma Less << | PHASE2 | RECRUITING | 2026-06-01 | Mayo Clinic, Jacksonville, Flo... More >>rida, 32224, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|Washington University in St. Louis, Saint Louis, Missouri, 63130, United States|Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less << |
NCT02831530 | Breast Cancer | PHASE2 | COMPLETED | 2018-02-02 | Gustave Roussy, Villejuif, Val... More >> De Marne, 94805, France Less << |
NCT06678269 | Metastatic Breast Cancer|Stage... More >> IV Breast Cancer|Breast Cancer|Breast Cancer Stage IV|Breast Cancer Metastatic|HER2-negative Breast Cancer|HER2 Negative Breast Carcinoma|Hormone-receptor-positive Breast Cancer Less << | PHASE1 | RECRUITING | 2028-11-30 | Memorial Sloan Kettering at Ba... More >>sking Ridge (All protocol activities), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ), Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York, 10065, United States|Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre, New York, 11553, United States Less << |
NCT02792725 | Metastatic Breast Cancer | APPROVED_FOR_MARKETING | - | Pacific Cancer Care, Monterey,... More >> California, 93940, United States|UCLA Medical Center, Santa Monica, California, 90404, United States|Orlando Health, Inc, Orlando, Florida, 32806, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|University of Minnesota Medical Center, Fairview Lakes, Wyoming, Minnesota, 55092, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, 64111, United States|Memorial Sloan Kettering Cancer Center, Commack, New York, 11725, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|West Virginia University Hospital, Morgantown, West Virginia, 26506, United States Less << | |
NCT02846987 | Sarcoma|Dedifferentiated Lipos... More >>arcoma Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-07-25 | Memorial Sloan Kettering Cance... More >>r Center, New York, New York, 10065, United States Less << |
NCT03356223 | Head and Neck Cancer|Advanced ... More >>Cancer|Metastatic Cancer Less << | PHASE2 | COMPLETED | 2022-12-05 | H?pital Saint-André, Bordeaux,... More >> 33075, France|Centre Léon Bérard, Lyon, 69373, France|Centre Antoine Lassagne, Nice, 06189, France Less << |
NCT03891784 | Advanced Digestive System Neur... More >>oendocrine Neoplasm|Digestive System Neuroendocrine Tumor|Foregut Neuroendocrine Tumor|Hindgut Neuroendocrine Tumor|Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm|Metastatic Digestive System Neuroendocrine Neoplasm|Midgut Neuroendocrine Tumor|Pancreatic Neuroendocrine Tumor|Refractory Digestive System Neuroendocrine Neoplasm Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2026-09-30 | University of Colorado, Denver... More >>, Colorado, 80217, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, 98109, United States Less << |
NCT03339843 | Esophageal Adenocarcinoma|Esop... More >>hagus SCC|Cholangiocarcinoma|Urothelial/Bladder Cancer, Nos|Endometrial Cancer Less << | PHASE2 | COMPLETED | 2023-12-20 | Universitair Ziekenhuis, Antwe... More >>rpen, Belgium|Institut Jules Bordet, Bruxelles, 1000, Belgium|Algemeen Ziekenhuis Groeninge, Kortrijk, 8500, Belgium|CHC Saint-Joseph, Liège, 4000, Belgium|CHU Ambroise Paré, Mons, 7000, Belgium|CHU UCL Namur Sainte-Elisabeth, Namur, 5000, Belgium|Centre Oscar Lambret, Lille, 59000, France|Institut Paoli-Calmettes, Marseille, 13009, France|Centre Henri Becquerel, Rouen, 76038, France|H?pital universitaire de Strasbourg - ICANS, Strasbourg, 67000, France|IUCT Oncopole - Institut Claudius Regaud, Toulouse, 31059, France Less << |
NCT04552769 | Thyroid Cancer|Anaplastic Thyr... More >>oid Cancer|Undifferentiated Thyroid Cancer Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2024-12-31 | Stanford University, Stanford,... More >> California, 94305, United States Less << |
NCT02308020 | Breast Cancer|Non-small Cell L... More >>ung Cancer|Melanoma|Brain Metastases Less << | PHASE2 | COMPLETED | 2019-11-08 | City of Hope National Medical ... More >>Center, Duarte, California, 91010, United States|University of California - San Diego, La Jolla, California, 92037-0845, United States|Univ of California San Francisco, San Francisco, California, 94115, United States|John Wayne Cancer Institute, Santa Monica, California, 90404, United States|University of Colorado, Aurora, Colorado, 80045, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Florida Cancer Specialists, Fort Myers, Florida, 33916-2233, United States|H Lee Moffitt Cancer Center, Tampa, Florida, 33612-9497, United States|Kaiser Permanente Center for Health Research, Honolulu, Hawaii, 96819, United States|James Graham Brown Cancer Center, Louisville, Kentucky, 40202, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Washington University Medical Center, Saint Louis, Missouri, 63110, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States|Providence Health and Services, Portland, Oregon, 97213, United States|SMO Sarah Cannon Research Inst., Nashville, Tennessee, 37203, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, 6009, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, 2298, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southport, 4215, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woolloongabba, 4102, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, 1090, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussel, 1000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, 6000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, 3000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, 4000, Belgium|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ottawa, K1H 8L6, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille Cedex, 59020, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, 59037, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon Cedex 08, 69373, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris Cedex 05, 75248, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint-Brieuc, 22027, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse cedex 9, 31059, France|Hadassah Medical Center - Ein Karem, Jerusalem, 9112001, Israel|Sheba Medical Center, Tel Hashomer, 5265601, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cona, 44124, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, 16132, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, 35128, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, 00128, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, 08035, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, 28034, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, 41013, Spain Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.97mL 0.39mL 0.20mL |
9.87mL 1.97mL 0.99mL |
19.74mL 3.95mL 1.97mL |
|
Dissolving Methods |
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|